Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. CRB-701: Encouraging Phase 1 data presented at ASCO 2024, showing 44% ORR in metastatic urothelial cancer and 43% ORR in cervical cancer. Phase 1 dose escalation underway in USA and Europe.
2. CRB-913: Phase 1 study for obesity treatment expected to commence in Q1 2025.
3. CRB-601: FDA cleared IND, Phase 1 study expected to initiate in Q4 2024.
4. Financial Results: Net loss of $10.0 million for Q2 2024. Cash, cash equivalents, and investments of $147 million as of June 30, 2024, expected to fund operations through Q3 2027.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in two upcoming investor conferences in August 2024. CEO Yuval Cohen, Ph.D., will provide corporate updates and engage in investor meetings at these events:
1. BTIG Virtual Biotechnology Conference (August 5-6, 2024): Invitation-only, one-on-one investor meetings.
2. Wedbush PacGrow Healthcare Conference (August 13-14, 2024): Invitation-only, one-on-one and small group investor meetings.
Interested investors should contact their respective BTIG or Wedbush representatives to arrange meetings with Corbus management during these conferences.
Corbus Pharmaceuticals announced promising clinical data for SYS6002 (CRB-701), a Nectin-4 targeting antibody drug conjugate, during the ASCO 2024 conference.
The Phase 1 trial has enrolled 37 patients since January 2024, with 25 evaluated for efficacy. SYS6002 showed a 44% ORR and 78% DCR in metastatic urothelial cancer (mUC), and a 43% ORR and 86% DCR in cervical cancer at doses ≥ 1.2 mg/Kg.
No dose-limiting toxicities were observed up to 4.5 mg/Kg. Notable adverse events included three cases of skin rash and one instance of grade 1 neuropathy, all resolved. Pharmacokinetic data demonstrated lower free MMAE levels than enfortumab vedotin across all doses.
The trial continues to show SYS6002's safety and efficacy, with the U.S. clinical study expected to complete in Q4 2024, with data presentation in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update at the 45th Annual Goldman Sachs Global Healthcare Conference in Miami Beach, FL, from June 10-13, 2024. The presentation is scheduled for June 12, 2024, at 2:40 p.m. ET. Investors will have the opportunity to participate in one-on-one meetings with the CEO. The presentation will be webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that an abstract titled 'Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701)' will be presented at the 2024 ASCO Annual Meeting. This presentation will occur on June 1, 2024, and will provide updated clinical data from a Phase 1 trial. The trial involves dose escalation spanning seven levels and employs a Bayesian Optimal Interval design. The study aims to establish the Maximum Tolerated Dose (MTD) and Phase 2 dose for SYS6002 (CRB-701) in patients with advanced solid tumors unresponsive to standard treatments. Key findings include safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The study is conducted in China by Corbus's partner CSPC, with a parallel Phase 1 study recently initiated in the U.S., where the first patient was dosed in April 2024.
Corbus Pharmaceuticals Holdings, Inc. will partake in the 2024 RBC Capital Markets Global Healthcare Conference. Yuval Cohen, the CEO, will engage in a fireside chat and investor meetings on May 14-15, 2024, in New York. The event will include a webcast on May 14 at 9:30 a.m. ET.
Corbus Pharmaceuticals reported its first-quarter 2024 financial results, highlighting the dosing of the first patient in the U.S. Phase 1 clinical trial of CRB-701, targeting Nectin-4. The company raised $116 million in capital, extending its cash runway through Q1 2027, and appointed Dr. Dominic Smethurst as Chief Medical Officer. CRB-701 Phase 1 data will be presented at ASCO Annual Meeting on June 1, 2024.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) will participate in the BTIG Obesity Health Forum with CEO Yuval Cohen joining a panel discussion on CB1 Axis Therapies for Obesity on May 8, 2024. The event will be held virtually, offering insights into the company's innovative approaches to addressing obesity.
Summary not available.
Summary not available.